4.7 Letter

Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity

Related references

Note: Only part of the references are listed.
Article Multidisciplinary Sciences

Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism

Nathan J. Schauer et al.

SCIENTIFIC REPORTS (2020)

Article Multidisciplinary Sciences

Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers

Peter Tsvetkov et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

Review Immunology

Restoring Natural Killer Cell immunity against Multiple Myeloma in the era of New Drugs

Gianfranco Pittari et al.

FRONTIERS IN IMMUNOLOGY (2017)

Review Pharmacology & Pharmacy

Molecular basis of resistance to proteasome inhibitors in hematological malignancies

Denise Niewerth et al.

DRUG RESISTANCE UPDATES (2015)

Article Oncology

Therapeutic Advances in Relapsed or Refractory Multiple Myeloma

Kenneth C. Anderson

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)

Review Oncology

The resistance mechanisms of proteasome inhibitor bortezomib

Shuqing Lu et al.

BIOMARKER RESEARCH (2013)